hC Bioscience
Latest round
- Series A
Last raised
- Feb 2023
Total raised
- $20M
Investors
- 6
About hC Bioscience
Founded in 2021 by CEO Leslie J. Williams, and based in Massachusetts, US, hC Bioscience, Inc. operates as a biotechnology company that develops and discovers tRNA (Transfer RNA) therapy for protein diseases. In February 2023, hC Bioscience, Inc. The company develops engineered tRNAs to overcome disease-causing issues in the genetic code as proteins are made. The company's PTCX (“Patch”) platform uses engineered tRNAs to recognize nonsense mutations in mRNA transcripts and suppresses them by inserting an amino acid where it is needed, restoring the protein to full length and function. The company is also developing a second tRNA-based platform called SWTX (“Switch”) to target diseases caused by missense mutations.
Who invested in hC Bioscience
6 investors across 3 rounds
See all investors in hC Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about hC Bioscience
Who invested in hC Bioscience?
hC Bioscience has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has hC Bioscience raised?
hC Bioscience has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did hC Bioscience last raise money?
hC Bioscience's most recent round on record is a Series A, in Feb 2023.
What does hC Bioscience do?
Founded in 2021 by CEO Leslie J.
Where is hC Bioscience headquartered?
hC Bioscience is headquartered in Cambridge, US.
Which VCs invest in companies like hC Bioscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at hC Bioscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like hC Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.